Wall Street closed lower on Tuesday, eagerly awaiting the Fed meeting. Market participants showed restraint in trading ahead of the Fed's last policy announcement of 2024 after economic data released on the day suggested that consumer spending was going up. The three most widely followed indexes closed the session in the red.
The Dow Jones Industrial Average (DJI) ticked down 266.93 points, or 0.6%, to close at 43,450.55. Twenty components of the 30-stock index ended in negative territory, Nine ended in positive, while one was unchanged. For the Dow, this was a ninth straight session of decline.
The tech-heavy Nasdaq Composite fell 64.83 points, or 0.3%, to close at 20,109.06.
The S&P 500 lost 23.45 points, or 0.4%, to close at 6,050.63. Ten of the 11 broad sectors of the benchmark index closed in the red. The Industrials Select Sector SPDR (XLI), the Communication Services Select Sector SPDR (XLC) and the Energy Select Sector SPDR (XLE) declined 0.9%, 0.8% and 0.7%, respectively, while the Consumer Discretionary Select Sector SPDR (XLY) advanced 0.3%.
The fear-gauge CBOE Volatility Index (VIX) increased 8% to 15.87. A total of 16.2 billion shares were traded on Tuesday, higher than the last 20-session average of 14.1 billion. Decliners outnumbered advancers by a 2.77-to-1 ratio on the NYSE, while on the Nasdaq Composite, declining issues had an 1.79-to-1 advantage.
While the markets have completely priced in another 25 basis point rate cut decision by the Fed to be announced from its December meet on Wednesday, a general consensus among investors is that there will be a rate-cut pause January onward.
It is highly unlikely, with the economic indicators being where they are, that the central bank would continue to cut rates before inflation numbers are favorable. Tuesday’s trade kind of mirrored a standard fare for a pre-Fed day market where the outlook is little uncertain, yet market participants are broadly aware what the Fed Chair’s guidance is going to be like.
Consequently, there was a broad-based slowdown evident in trading. Shares of Broadcom Inc. AVGO and Moderna, Inc. MRNA fell 3.9% and 2.6%, respectively. Both currently carry a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Per the U.S. Census Bureau, advance estimates of U.S. retail and food services sales for November 2024 came in at $724.6 billion, up 0.7% from October. The October number was revised up to 0.5% from the previously reported 0.4%.
Core retail sales, which excludes autmobiles, came in at an increase of 0.2% for November. The number for October was revised upto an increase of 0.2% from the previously reported 0.1%.
Per a report by the Federal Reserve, Industrial Production for November came in at a decrease of 0.1%. The number for October was revised up to a decrease of 0.4% from the previously reported 0.3% decrease.
Capacity Utilization for November came in at 76.8 per the same report. The number for October was revised down to 77 from the previously reported 77.1.
Per the U.S. Census Bureau, Business Inventories for October, adjusted for seasonal and trading day differences but not for price changes, were estimated at an end-of-month level of $2,587 billion, up 0.1% from September 2024.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Moderna, Inc. (MRNA) : Free Stock Analysis Report
Broadcom Inc. (AVGO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.